Novavax’s COVID-19 vaccine shows immunity against the Eris subvariant; infants with excessive screen time are at higher risk of developmental delays; a near-total abortion ban is expected to go into effect in Indiana within days.
In an announcement, Novavax stated that its updated protein-based COVID-19 vaccine has shown promise in generating an immune response against emerging forms of the virus, including the Eris subvariant, in animal studies, according to Reuters. Novavax's vaccine demonstrated virus-neutralizing antibodies against multiple XBB subvariants, including EG.5.1 and XBB.1.16.6, in preclinical studies. Eris accounts for more than 17% of COVID-19 cases in the United States and has been classified as a "variant of interest" by the World Health Organization due to potential mutations that may affect its transmissibility and severity.
Excessive screen time during infancy, ranging from 1 to 4 hours per day, has been associated with a higher risk of developmental delays in communication, fine motor skills, problem-solving, and personal and social skills by age 2 years, according to CNN. In a study published in JAMA Pediatrics involving more than 7000 children, research highlights the importance of mindful and age-appropriate screen time for young children and underscores the significance of quality interactions and activities to support healthy development. Experts recommend alternatives such as reading, coloring, and interactive play to encourage well-rounded growth in infants.
A near-total abortion ban is set to take effect in the near future following the Indiana Supreme Court's denial of a rehearing in a case brought by the American Civil Liberties Union of Indiana, according to the Associated Press. The court had previously upheld the ban on June 30, ruling that it did not violate the state's constitution. Once the ruling is certified, the ban is expected to take effect within days. This decision comes amid a wave of restrictions on abortion rights in conservative states following discussions surrounding the overturning of Roe v Wade.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More